Monopar Therapeutics Correlations

MNPR Stock

USD 37.39 2.61 6.52%

The current 90-days correlation between Monopar Therapeutics and Acrivon Therapeutics, Common is -0.03 (i.e., Good diversification). The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Monopar Therapeutics Correlation With Market

Significant diversification

The correlation between Monopar Therapeutics and DJI is 0.05 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and DJI in the same portfolio, assuming nothing else is changed.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

Moving together with Monopar Stock

0.78	PLX	Protalix Biotherapeutics	Pair Corr
0.62	MLSS	Milestone Scientific Earnings Call This Week	Pair Corr
0.61	WM	Waste Management	Pair Corr
0.82	GE	GE Aerospace	Pair Corr
0.64	WMT	Walmart Aggressive Push	Pair Corr
0.73	MMM	3M Company	Pair Corr
0.76	JPM	JPMorgan Chase	Pair Corr
0.65	IBM	International Business	Pair Corr

Moving against Monopar Stock

0.55	CDIO	Cardio Diagnostics	Pair Corr
0.53	CRNX	Crinetics Pharmaceuticals	Pair Corr
0.4	ASMB	Assembly Biosciences Earnings Call This Week	Pair Corr
0.33	SCLX	Scilex Holding	Pair Corr
0.71	MRK	Merck Company	Pair Corr

Related Correlations Analysis

	ANEB	ACRV	PMVP	MOLN	MLYS	CADL	ACXP	SCPH	DMAC
ANEB		-0.03	0.05	-0.08	0.37	-0.09	0.03	0.12	-0.32	ANEB
ACRV	-0.03		0.7	0.39	0.1	-0.16	0.51	0.21	-0.33	ACRV
PMVP	0.05	0.7		0.56	-0.21	0.03	0.81	0.66	-0.11	PMVP
MOLN	-0.08	0.39	0.56		-0.59	-0.33	0.73	0.48	-0.03	MOLN
MLYS	0.37	0.1	-0.21	-0.59		0.03	-0.48	-0.42	-0.56	MLYS
CADL	-0.09	-0.16	0.03	-0.33	0.03		-0.1	0.23	0.28	CADL
ACXP	0.03	0.51	0.81	0.73	-0.48	-0.1		0.7	0.1	ACXP
SCPH	0.12	0.21	0.66	0.48	-0.42	0.23	0.7		0.13	SCPH
DMAC	-0.32	-0.33	-0.11	-0.03	-0.56	0.28	0.1	0.13		DMAC
	ANEB	ACRV	PMVP	MOLN	MLYS	CADL	ACXP	SCPH	DMAC

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

ACXP	+ 0.81	PMVP
ACXP	+ 0.73	MOLN
PMVP	+ 0.7	ACRV
SCPH	+ 0.7	ACXP
SCPH	+ 0.66	PMVP
MOLN	+ 0.56	PMVP

High negative correlations

MLYS	- 0.59	MOLN
DMAC	- 0.56	MLYS
ACXP	- 0.48	MLYS
SCPH	- 0.42	MLYS
CADL	- 0.33	MOLN
DMAC	- 0.33	ACRV

Risk-Adjusted Indicators

There is a big difference between Monopar Stock performing well and Monopar Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Monopar Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
ANEB	5.72	0.62	0.10	0.37	5.70	(8.10)	19.58	(10.43)	40.87
ACRV	4.13	(0.16)	0.00	(0.16)	0.00	0.00	10.17	(8.24)	30.57
PMVP	1.83	(0.24)	0.00	(0.29)	0.00	0.00	4.41	(3.31)	16.42
MOLN	2.72	(0.28)	0.00	(0.21)	0.00	0.00	7.84	(7.39)	20.58
MLYS	4.29	0.63	0.17	(0.45)	4.26	(4.97)	10.04	(8.23)	50.53
CADL	5.36	0.76	0.09	0.31	7.02	(5.67)	10.20	(11.92)	75.98
ACXP	5.47	(0.74)	0.00	(6.67)	0.00	0.00	9.72	(15.29)	51.70
SCPH	2.15	(0.04)	0.00	(0.16)	0.00	0.00	4.86	(4.09)	12.76
DMAC	3.31	0.08	0.02	0.02	4.76	(3.34)	5.71	(5.88)	47.69

Monopar Therapeutics Corporate Executives

Elected by the shareholders, the Monopar Therapeutics' board of directors comprises two types of representatives: Monopar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monopar. The board's role is to monitor Monopar Therapeutics' management team and ensure that shareholders' interests are well served. Monopar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monopar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

Christopher Starr	CoFounder Board	Profile
Quan Vu	Principal CFO	Profile
Kim CPA	Secretary, CFO	Profile
Karthik CFA	Principal CFO	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC